Related Experiment Video

Updated: Jun 23, 2026

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

[Prognostic value of big endothelin-1 prognostic value in patients with heart failure and moderately symptomatic

Esther Roselló-Lletí1, Miguel Rivera, Vicente Miró

  • 1Unidad de Cardiología, Centro de Investigación del Hospital Universitario La Fe, Valencia, España. rivera_jmi@gva.es

Medicina Clinica
|April 21, 2009
PubMed

Insights

Big endothelin-1 effectively predicts cardiovascular mortality in heart failure (HF) patients with moderate symptoms. This finding supports its use as a prognostic marker in this specific HF population.

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Research
  • Heart Failure Pathophysiology

Context:

  • Previous studies focused on severe heart failure (HF) patients.
  • The prognostic value of big endothelin-1 in moderately symptomatic HF was unclear.
  • Big endothelin-1 is implicated in cardiovascular regulation.

Purpose:

  • To evaluate the prognostic power of big endothelin-1 in patients with moderately symptomatic heart failure.
  • To assess big endothelin-1 as a predictor of cardiovascular mortality over a 24-month follow-up.
  • To determine a reliable cut-off value for big endothelin-1 in this patient group.

Summary:

  • Big endothelin-1 levels were measured in 90 outpatients with heart failure (HF), classified by NYHA functional class.
  • The study found big endothelin-1 predicted cardiovascular mortality with an AUC of 0.68 (P=.02), identifying a cut-off of 0.98 fmol/ml.
  • Logistic regression confirmed big endothelin-1 as an independent predictor of mortality (OR=5.851, P=.009).

Impact:

  • Big endothelin-1 demonstrates prognostic value in moderately symptomatic heart failure patients.
  • This research identifies a potential biomarker for risk stratification in a previously underserved HF population.
  • Findings may guide clinical decisions and therapeutic strategies for HF management.
Abstract

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.